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without clinically signiﬁcant GvHD, we previously identiﬁed a
panel of CML-associated antigens that are targets of antibodies
present in post-DLI sera. To gain insight into the possible mech-
anisms of immunogenicity of our GvL-associated target antigens,
we surveyed previously known cellular functions of our entire
panel of identiﬁed antigens, and observed that 70% are nucleic
acid binding proteins, thus predicting that sera from DLI respond-
ers may contain nucleic-acid containing activities that stimulate
immunity. Indeed, 5 of 6 post-DLI sera, but not pre-DLI sera,
induced a 3 to 50-fold increase in the expression of MIP-1alpha,
TNF-alpha, IP-10 and IFN-alpha transcripts in normal peripheral
blood mononuclear cells (PBMC). Cytokines were also not in-
duced by sera from 3 of 3 DLI non-responders or 3 of 3 CML
patients who achieved molecular remission after imatinib treat-
ment. This endogenous immunostimulatory factor required both
nucleic acid and protein for its adjuvant activity as pretreatment of
post-DLI sera with DNase, RNase, papain or pepsin resulted in
marked decrease in cytokine induction. To test for the role of
distinct TLRs in this response, HEK transfectants expressing
TLR3, 4, 8 or 9 were exposed to sera collected 6-12 months after
DLI. IL-8 expression increased only in the TLR8 and TLR9-
expressing cell lines that are known to be responsive to RNA and
DNA respectively. IL-8 expression was further induced by post-
DLI sera in TLR9-expressing cell lines co-transfected with CD32,
suggesting that internalization by FcR may enhance delivery of
nucleic acids to endosomal TLR8/9. None of the transfectants
could be activated by pre-DLI sera, nor by post-DLI sera from
non-responders. Finally, sera from responders collected as early as
2 weeks after DLI consistently activated TLR8 and 9 suggesting
that endogenous TLR8/9 activation may contribute to the early
immunologic events involved in effective DLI responses. Taken
together, these studies demonstrate for the ﬁrst time that effective
tumor immunity is correlated with the presence of endogenous
adjuvant-like nucleic-acid-immunoglobulin complexes in patient
sera. Ongoing studies are focused on studying the immunologic
effects of this endogenous adjuvant and determining which of our
previously identiﬁed CML antigens are bound to nucleic acids that
activate TLR8 and TLR9.
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CYTOTOXIC T LYMPHOCYTE RESPONSES TO PR1 PEPTIDE IN CML
PATIENTS INVERSELY CORRELATE WITH PROTEINASE 3 AND ELAS-
TASE EXPRESSION BUT DONOR PR1-RESPONSES DETERMINE MOLEC-
ULAR REMISSION AND DISEASE ERADICATION AFTER STEM CELL
TRANSPLANTATION
Yong, A.S.M.1, Rezvani, K.1, Savani, B.N.1, Eniafe, R.1, Mielke, S.1,
Goldman, J.M.1, Barrett, J.1 1NHLBI/NIH, Hematology Branch, 10
Center Drive, Bethesda, MD.
The primary granule proteins (PGP) neutrophil elastase (ELA2)
and proteinase 3 (PR3) both contain the nonapeptide PR1 which
can induce cytotoxic T lymphocyte (CTL) responses in chronic
myeloid leukemia (CML). The relative contribution of PR3 and
ELA2 to PR1 expression is not known. We previously found that
higher levels of PR3 and ELA2 gene expression in CD34 pro-
genitor cells were associated with longer survival in CML patients.
Eradication of leukemia requires elimination of leukemic stem
cells, which reside within the CD34 progenitor cell pool. We
therefore studied PGP expression and T cell response to PR1 in 31
CML patients and their HLA-identical family donors prior to
T-cell depleted allogeneic stem cell transplantation (SCT) with
T-cell add-back on day 45-100 post-SCT. CD8 T cells and
CD34 progenitor cells were puriﬁed from mononuclear cells
(MNC) of cryopreserved leukapheresis products from HLA-
A*0201 CML patients and their donors. ELA2 and PR3 gene
expression in MNC and CD34 cells was measured using real-
time quantitative polymerase chain reaction (RQ-PCR). To assess
PR1-CTL responses, T2 cells were loaded with PR1 peptide
(VLQELNVTV) and subsequently co-cultured with CD8 T
cells. PR1-CTL response was measured as interferon- mRNA
expression (relative to CD8) obtained by RQ-PCR. PR1-speciﬁc
CTL responses were detected in 7/28 CML patients and 7/27
HLA-identical donors. In CML patients, pre-SCT expression of
both PR3 and ELA2 in MNC was strongly correlated with the
expression in CD34 cells (p0.009 and p0.0006 respectively).
There was an inverse relationship between PR1-CTL response in
CML patients pre-SCT and PR3 or ELA2 expression (p0.02 and
p0.01 respectively). This data suggest that both PR3 and ELA2
expression in CD34 cells and their progeny are a potential source
of PR1. However, high expression of these proteins may result in
selective deletion of PR1 T cell clones. The presence of PR1-
responses in HLA-identical donors was associated with a signiﬁ-
cantly improved molecular remission rate from 3 months post-
SCT onwards, and moreover, was predictive of molecular
remission at 1-year post-SCT (p0.003). These ﬁndings support
peri-transplant vaccination strategies with PR1 peptide to eradicate
minimal residual disease. Conversely, in untransplanted patients,
the lower PR1 response in the presence of high PGP expression
suggests that vaccines given to patients with minimal residual
disease could result in tolerance to the leukemia.
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CD18 SEPARATES GVHD AND GVL EFFECT
Liang, Y.1, Anasetti, C.1, Yu, X.-Z.1 1H. Lee Mofﬁtt Cancer Center &
Research Institute, Tampa, FL.
Graft-versus-host disease (GVHD) remains a major cause of
morbidity and mortality in allogeneic hematopoietic stem cell
transplantation. Migration of donor-derived T cells into GVHD
target organs plays an essential role in the development of GVHD.
Beta2 integrins, a group of heterodimeric molecules including
CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1), CD11c/CD18
and CD11d/CD18, are of critical importance for leukocyte extrav-
asation through vascular endothelia and for T cell activation. We
asked whether CD18-deﬁcient T cells would induce less GVHD
while sparing graft-versus-leukemia (GVL) effect. In murine allo-
geneic bone marrow transplantation (BMT) models, we found that
recipients of CD18-/- donor T cells had signiﬁcantly less GVHD
morbidity and mortality compared with recipients of WT donor T
cells. A cell-dose titration experiment indicated that the ability of
CD18-/- T cells had more than 4-fold reduction compared to that
of WT T cells in the induction of GVHD. Analysis of alloreactive
showed that CD18-/- and WT T cells had comparable activation,
expansion and cytokine production in vivo. Reduced GVHD was
associated with a signiﬁcant decrease in donor-T cell inﬁltration of
recipient intestine and with an overall decrease in pathologic scores
in intestine and liver. Finally, we found that in vivo GVL effect of
CD18-/- donor T cells was largely preserved, because mortality of
the recipients transplanted with CD18-/- T cells plus tumor cells
was greatly delayed or prevented. Our data suggest that strategies
to target beta2 intergrin have clinical potential to alleviate or
prevent GVHD while sparing GVL activity.
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INHIBITION OF HMG-COA REDUCTASE ACTIVITY WITH STATINS PRO-
VIDES ACUTE-GRAFT-VERSUS-HOST DISEASE PROTECTION BY TH-2
CYTOKINE INDUCTION WHILE SPARING GRAFT-VERSUS-LEUKEMIA
ACTIVITY
Zeiser, R.1, Youssef, S.2, Baker, J.1, Steinman, L.2, Negrin, R.1 1Stan-
ford University Department of Medicine, Stanford, CA; 2Stanford Uni-
versity Department of Neurology, Stanford, CA.
The beneﬁcial impact of 3-hydroxy-3-methyl-CoA reductase in-
hibitors (statins) on autoimmunity and allograft rejection is well
documented. To investigate whether statins are capable of protect-
ing from acute graft vs host disease (aGVHD) we utilized an
established murine model (FVB/N into Balb/c). Type II statins
were potent inducers of a T-helper cell (Th)-2 cytokine proﬁle in
the adoptively transferred T cells upon exposure in vitro or in vivo.
Expansion of alloreactive luciferase transgenic T cells as measured
by total body light emission was signiﬁcantly reduced by donor
pre-treatment (10mg/kg) or in vitro T cell treatment (10nM) with
atorvastatin (AT vs PBS; p0.0008). The beneﬁcial effect of statin
treatment translated into signiﬁcantly reduced aGvHD lethality in
statin as compared to PBS treated animals. Th-2 biased donor T
cells could be tracked until day 25 after BMT. Host treatment
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